ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Items In This Category

 TitleCreatedDownload
application/pdfDrug Safety update MHRA February-2021-DSU-PDF_final.pdf (300KB)23/02/2021Download
 Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury. injury page 2 Pregabalin (Lyrica): reports of severe respiratory depression. Alkindi (hydrocortisone... 
application/pdfDrug Safety Update MHRA January 2021 PDF.pdf (361KB)07/01/2021Download
  Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review page: COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice. Dimethyl fumarate... 
application/pdfDrug Safety Update MHRA December 2020-DSU-PDF-1712.pdf (263KB)18/12/2020Download
 Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk: Erythromycin: caution required due to cardiac risks (QT... 
application/pdfDrug Safety Update MHRA November 2020 PDF.pdf (308KB)16/11/2020Download
 Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy. Pirfenidone (Esbriet): risk of serious liver injury, and updated advice on liver function testing . Ferric... 
application/pdfDrug Safety Update MHRA October 2020.pdf (295KB)22/10/2020Download
 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity. Flucytosine (Ancotil): new... 
application/pdfDrug Safety Update MHRA September 2020 PDF.pdf (279KB)24/09/2020Download
 Opioids: risk of dependence and addiction: Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients: Methotrexate once-weekly for autoimmune diseases: new measures to... 
application/pdfDrug Safety Update MHRA August 2020-DSU-PDF.pdf (306KB)01/09/2020Download
 Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available over-the-counter: new measures to support safe use. Clozapine and other antipsychotics: monitoring blood... 
application/pdfDrug Safety Update MHRA July-2020-DSU-PDF.pdf (203KB)31/07/2020Download
 Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection. Liposomal and lipid-complex formulations: name change to reduce medication errors  
application/pdfDrug Safety Update MHRA June-2020-DSU-PDF.pdf (286KB)29/06/2020Download
  
application/pdfDrug Safety Update MHRA May-2020-DSU.pdf (244KB)21/05/2020Download
  
application/pdfDrug Safety Update MHRA April-2020 PDF.pdf (194KB)28/04/2020Download
  
application/pdfDrug Safety Update MHRA March-2020-PDF.pdf (301KB)07/04/2020Download
 Esmya - licence suspended: tofacitinib [Xeljanz] - new measures to minimise risk of VTE & of serious and fatal infections: Baricitinib - risk of venous thromboembolism 
Page: [1] [2] [3] [4] [5] [6] [7]
[ Next » ]